1) Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review2) What's Trending: CRISPR gene editing in neuromuscular diseases3) Neurology Today® paper – spotlight on Dr. John NoseworthyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 14, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Hugh Markus about his paper on the prognosis of carotid dissecting aneurysms. For our "What's Trending" feature of the week, Dr. Ted Burns interviews Dr. Eric Olson regarding CRISPR at the 2016 AANEM meeting. In the next part of the podcast, Dr. Ted Burns speaks with Mayo Clinic CEO Dr. John Noseworthy about his meeting with President Trump and his experience as Editor-in-Chief of Neurology. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Markus has served on the editorial boards of the International Journal of Stroke, Clinical Neurology and Neurosurgery, BMC Medicine, and Frontiers in Neurology; receives publishing royalties from Oxford University Press; has received reimbursement from Astra Zeneca for teaching a session to employees; and has received research support from NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Noseworthy receives publishing royalties for the following publications: Fifty Neurologic Cases, Oxford, 2004, Multiple Sclerosis 2, Blue Books; Butterworth, 2003, Neurologic Therapeutics, Edition 1, Martin Dunitz, 2003, Neurologic Therapeutices, Edtion 2, Informa, 2006, McAlpine's Multiple Sclerosis, 4th Edition, 2006.All other participants have no disclosures.